Added to YB: 2025-12-01
Pitch date: 2025-10-01
NAGE [bearish]
Niagen Bioscience, Inc.
+20.38%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products.
Market Cap
$512.6M
Pitch Price
$8.00
Price Target
N/A
Dividend
N/A
EV/EBITDA
21.10
P/E
27.25
EV/Sales
3.62
Sector
Life Sciences Tools and Services
Category
special_situation
Show full summary:
Niagen Bioscience, Inc. - $NAGE (short)
NAGE: FDA just re-legalized NMN (primary competitor to NAGE's NR supplement), ending 2-year ban that drove growth. NMN dominates 50% market share ex-US vs 25% for NR. $77M revenue biz trading 6x sales, 30x FCF on broken growth story. 4 analysts missed NMN catalyst. Expects consumer switchback to hurt numbers.
Read full article (4 min)